Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCD411
- Development stage
- Phase 3
- Lead developer
- Sam Chun Dang Pharm
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravitreal
01
Overview
SCD411 is a proposed biosimilar to aflibercept (marketed as Eylea), developed for the treatment of neovascular (wet) age-related macular degeneration. Like reference aflibercept, SCD411 is a recombinant fusion protein produced in Chinese hamster ovary cells using recombinant DNA technology. It acts by binding to vascular endothelial growth factor A (VEGF-A) and placental growth factor (PGF), thereby inhibiting their activity and preventing abnormal blood vessel growth in the eye. Clinical studies have demonstrated that SCD411 has equivalent efficacy, safety, pharmacokinetics, and immunogenicity compared with reference aflibercept[1][6][7]. The drug is administered via intravitreal injection.
- Other names
- aflibercept biosimilar
02
Targets
PGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on SCD411.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCD411.